Seattle Genetics Inc.
21823 30th Drive SE
Bothell,
WA 98021
United States - Map
Phone: 425-527-4000
Fax: 425-527-4001
Web Site: http://www.seattlegenetics.com
| Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma under a special protocol assessment. The companys other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; and SGN-70, a humanized anti-CD70 antibody. In addition, its product candidates in development comprise SGN-75 for CD70-positive hematologic malignancies and solid tumors; AGS-5ADC for solid tumors; and SGN-19A for CD19-positive hematologic malignancies. It has a collaboration agreement with Genentech, Inc. to develop and commercialize Dacetuzumab; with Genentech, Inc., Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., and MedImmune Inc. for the companys antibody-drug conjugates (ADC) technology; and an ADC co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Clay B. Siegall Ph.D., 48
Co-Founder, Interim Chairman, Chief Exec. Officer and Pres |
$
928.00K |
$
132.00K | Mr. Todd E. Simpson , 48
Chief Financial Officer and Principal Accounting Officer |
$
445.00K |
$
0 | Dr. Morris Z. Rosenberg D.Sc., 49
Exec. VP of Process Sciences |
$
409.00K |
$
232.00K | Dr. Thomas C. Reynolds M.D., Ph.D., 50
Chief Medical Officer |
$
533.00K |
$
48.00K | Mr. Eric L. Dobmeier J.D., 40
Chief Bus. Officer and Corp. Sec. |
$
532.00K |
$
287.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.20% Nasdaq 
0.055 (0.59%) 
Profile
